Serotonergic mechanisms in Parkinson's disease: Opposing results from preclinical and clinical data

Journal of Neural Transmission

Volumn 113, Issue 1, 2006, Pages 59-73

  Scholtissen, B ^a   Verhey, F R J ^a   Steinbusch, H W M ^a   Leentjens, A F G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Functional intervention; Parkinson's disease; Serotonin

Indexed keywords

1 METHYL 4 PHENYL 4 PIPERIDINOL PROPIONATE; 1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 5 HYDROXYTRYPTOPHAN; CARBOXYLYASE; CISAPRIDE; DESIPRAMINE; DEXFENFLURAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; LEVODOPA; METHYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEFAZODONE; ONDANSETRON; PETHIDINE; PIPERIDINE DERIVATIVE; PYRIDOXINE; QUETIAPINE; RESERPINE; RITANSERIN; SEROTONIN; SEROTONIN 2C ANTAGONIST; SEROTONIN ANTAGONIST; SUMATRIPTAN; TRYPTOPHAN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DRUG EFFECT; HUMAN; MENTAL DETERIORATION; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR; VISUAL HALLUCINATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN; SEROTONIN AGENTS;

EID: 29244489587     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0368-3     Document Type: Review

References (101)

1. A Aberg-Wistedt L Hasselmark R Stain-Malmgren B Aperia BF Kjellman AA Mathe 1998 Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 97 5 374 380
2. Adams RD, Victor M (1993) Priciples of neurology. McGraw-Hill, New York
3. R Arai N Karasawa I Nagatsu 1996 Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 706 1 177 179
4. A Avila X Cardona M Martin-Baranera P Maho F Sastre J Bello 2003 Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 23 5 509 513
5. C Baeken H D'Haenen P Flamen J Mertens D Terriere K Chavatte R Boumon A Bossuyt 1998 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med 25 12 1617 1622
6. A Balcioglu K Zhang FI Tarazi 2003 Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119 4 1045 1053
7. BL Beasley RW Davenport TN Chase 1977 Fenfluramine hydrochloride treatment of parkinsonism. Arch Neurol 34 4 255 256
8. S Benloucif MP Galloway 1991 Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200 1 1 8
9. S Benloucif MJ Keegan MP Galloway 1993 Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265 1 373 377
10. W Birkmayer JD Birkmayer 1987 Dopamine action and disorders of neurotransmitter balance. Gerontology 33 3-4 168 171
11. W Birkmayer W Danielczyk E Neumayer P Riederer 1972 The balance of biogenic amines as condition for normal behaviour. J Neural Transm 33 2 163 178
12. Birkmayer W, Riederer P (1985) Biochemische Veranderungen bei der Parkinson-Krankheit. In: Birkmayer W, Riederer P (eds) Die Parkinson-Krankheit. Biochemie, Klinik, Therapie. Springer, Wien New York, pp 29-59
13. C Bishop PD Walker 2003 Combined intrastriatal dopamine d1 and serotonin 5-ht2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience 121 3 649 657
14. T Brucke J Kornhuber P Angelberger S Asenbaum H Frassine I Podreka 1993 SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm 94 2 137 146
15. RC Bryant 1980 Duration of illness and response to tryptophan in Parkinson's disease. Arch Neurol 37 10 677
16. GF Busatto LS Pilowsky DC Costa J Mertens D Terriere PJ Ell R Mulligan MJ Travis JE Leysen D Lui S Gacinovic W Waddington A Lingford-Hughes RW Kerwin 1997 Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. Eur J Nucl Med 24 2 119 124
17. GJ Canter R De La Torre M Mier 1961 A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 133 143 147
18. TN Chase 1972 Serotonergic mechanisms in Parkinson's disease. Arch Neurol 27 4 354 356
19. TN Chase 1974 Serotonergic mechanisms and extrapyramidal function in man. Adv Neurol 5 31 39
20. TN Chase LK Ng AM Watanabe 1972 Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology 22 5 479 484
21. CP Chen JT Alder L Bray AE Kingsbury PT Francis OJ Foster 1998 Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann NY Acad Sci 861 288 289
22. AJ Cleare RM Murray V O'Keane 1998 Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response. Biol Psychiatry 44 7 555 561
23. A Coppen M Metcalfe JD Carroll JG Morris 1972 Levodopa and L-tryptophan therapy in Parkinsonism. Lancet 1 7752 654 658
24. JL Cummings 1992 Depression and Parkinson's disease: a review. Am J Psychiatry 149 4 443 454
25. W Dauer S Przedborksi 2003 Parkinson's disease: mechanisms and models. Neuron 39 889 909
26. P De Deurwaerdere S Navailles KA Berg WP Clarke U Spampinato 2004 Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24 13 3235 3241
27. PL Delgado DS Charney LH Price GK Aghajanian H Landis GR Heninger 1990 Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47 5 411 418
28. PL Delgado DS Charney LH Price H Landis GR Heninger 1989 Neuroendocrine and behavioral effects of dietary tryptophan depletion in healthy subjects. Life Sci 45 2323 2332
29. R Deumens A Blokland J Prickaerts 2002 Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175 2 303 317
30. G Di Giovanni P De Deurwaerdere M Di Mascio V Di Matteo E Esposito U Spampinato 1999 Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91 2 587 597
31. V Di Matteo M Cacchio C Di Giulio E Esposito 2002 Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71 4 727 734
32. V Di Matteo A De Blasi C Di Giulio E Esposito 2001 Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22 5 229 232
33. M Doder EA Rabiner N Turjanski AJ Lees DJ Brooks 2003 Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60 4 601 605
34. JD Fernstrom RJ Wurtman B Hammarstrom-Wiklund WM Rand HN Munro CS Davidson 1979 Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. Am J Clin Nutr 32 9 1912 1922
35. SH Fox JM Brotchie 2000 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur J Pharmacol 398 1 59 64
36. SH Fox B Moser JM Brotchie 1998 Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine- lesioned rat model of Parkinson's disease. Exp Neurol 151 1 35 49
37. D Frechilla A Cobreros L Saldise R Moratalla R Insausti M Luquin J Del Rio 2001 Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 4 288 296
38. RW Fuller 1977 Fenfluramine and Parkinson's disease. Arch Neurol 34 11 720
39. P Gaspar A Febvret J Colombo 1993 Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96 1 100 106
40. R Gerber CA Altar JM Liebman 1988 Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 94 2 178 182
41. A Gobert JM Rivet F Lejeune A Newman-Tancredi A Adhumeau-Auclair JP Nicolas L Cistarelli C Melon MJ Millan 2000 Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36 3 205 221
42. TH Haapaniemi A Ahonen P Torniainen KA Sotaniemi VV Myllyla 2001 [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 16 1 124 130
43. CD Hall EA Weiss CE Morris AJ Prange Jr 1972 Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration. Neurology 22 3 231 237
44. J Henderson C Yiannikas JS Graham 1992 Effect of ritanserin, a higly selective 5-HT2 receptor antagonist, on Parkinson's disease. Clin Exp Neurol 29 277 282
45. J Hildebrand F Delecluse 1987 Effect of ritanserin, a selective serotonin-S2 antagonist, on Parkinson's rest tremor. Cur Ther Res 41 2 298 300
46. O Hornykiewicz 1986 Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 60 140 147
47. O Hornykiewicz 1998 Biochemical aspects of Parkinson's disease. Neurology 51 Suppl 2 S2 S9
48. MM Iravani MJ Jackson M Kuoppamaki LA Smith P Jenner 2003 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 23 27 9107 9115
49. BL Jacobs CA Fornal 1993 5-HT and motor control: a hypothesis. Trends Neurosci 16 9 346 352
50. JM Kent JD Coplan J Martinez W Karmally LA Papp JM Gorman 1996 Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res 64 2 83 90
51. L Kerenyi GA Ricaurte DJ Schretlen U [tmp] McCann J Varga WB Mathews HT Ravert RF Dannals J Hilton DF Wong Z Szabo 2003 Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60 9 1223 1229
52. SE Kim JY Choi YS Choe Y Choi WY Lee 2003 Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 44 6 870 876
53. SE Kim WY Lee YS Choe JH Kim 1999 SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res 21 3 255 261
54. T Klaassen J Klumperbeek NE Deutz HM van Praag E Griez 1998 Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Res 77 3 167 174
55. T Klaassen WJ Riedel A van Someren NE Deutz A Honig HM van Praag 1999 Mood effects of 24-hour tryptophan depletion in healthy first-degree relatives of patients with affective disorders. Biol Psychiatry 46 4 489 497
56. HL Klawans SP Ringel 1973 A clinical study of methysergide in Parkinsonism: evidence against a serotonergic mechanism. J Neurol Sci 19 4 399 405
57. DA Knobelman HF Kung I Lucki 2000 Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Ther 292 3 1111 1117
58. VS Kostic D Lecic M Doder J Marinkovic S Filipovic 1996 Prolactin and cortisol responses to fenfluramine in Parkinson's disease. Biol Psychiatry 40 8 769 775
59. JW Langston P Ballard JW Tetrud I Irwin 1983 Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 4587 979 980
60. N Laprade F Radja TA Reader JJ Soghomonian 1996 Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J Neurosci 16 11 3727 3736
61. B Lavoie A Parent 1990 Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299 1 1 16
62. HB Lebsanft A Mayerhofer KA Kovar WJ Schmidt 2003 Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent? J Neural Transm 110 7 707 718
63. AF Leentjens 2004 Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 17 3 120 126
64. Leentjens AFG (2002) Parkinson's disease, depression, and serotonin. Maastricht University, Maastricht
65. J Lehmann 1973 Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances. Acta Med Scand 194 3 181 189
66. DG LeMarquand RO Pihl SN Young RE Tremblay JR Seguin RM Palmour C Benkelfat 1998 Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males. Neuropsychopharmacology 19 4 333 341
67. G Lucas N Bonhomme P De Deurwaerdere M Le Moal U Spampinato 1997 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl) 131 1 57 63
68. G Lucas P De Deurwaerdere S Caccia S Umberto 2000 The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39 6 1053 1063
69. G Lucas U Spampinato 2000 Role of striatal serotonin2a and serotonin2c receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74 693 701
70. T Maeda K Kannari H Shen A Arai M Tomiyama M Matsunaga T Suda 2003 Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343 1 17 20
71. R Mayeux 1990 The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol 53 163 166
72. R Mayeux Y Stern L Cote JB Williams 1984 Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 34 5 642 646
73. EF [tmp] McCance-Katz KM Marek LH Price 1992 Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42 1813 1814
74. KS [tmp] McNaught DP Perl AL Brownell CW Olanow 2004 Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 1 149 162
75. L Mignon WA Wolf 2002 Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 163 1 85 94
76. E Miyawaki Y Meah WC Koller 1997 Serotonin, dopamine, and motor effects in Parkinson's disease. Clin Neuropharmacol 20 4 300 310
77. T Murai U Muller K Werheid D Sorger M Reuter T Becker DY von Cramon H Barthel 2001 In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13 2 222 228
78. S Navailles P De Deurwaerdere G Porras U Spampinato 2004 In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology 29 2 319 326
79. JL Neumeyer SY Wang RA Milius RM Baldwin Y Zea-Ponce PB Hoffer E Sybirska M al-Tikriti DS Charney RT Malison 1991 [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34 10 3144 3146
80. ME Newman B Shapira B Lerer 1998 Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int J Neuropsychopharmcol 1 1 49 69
81. SL Nicholson JM Brotchie 2002 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 9 Suppl 3 1 6
82. S Numan KH Lundgren DE Wright JP Herman KB Seroogy 1995 Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 29 2 391 396
83. JD Oh F Bibbiani TN Chase 2002 Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 177 2 557 564
84. M Orth SJ Tabrizi 2003 Models of Parkinson's disease. Mov Disord 18 7 729 737
85. SB Park JT Coull RH [tmp] McShane AH Young BJ Sahakian TW Robbins PJ Cowen 1994 Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 33 3-4 575 588
86. JM Rabey J Vardi JJ Askenazi M Streifler 1977 L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology 23 6 438 444
87. WJ Riedel T Klaassen NE Deutz A van Someren HM van Praag 1999 Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl) 141 4 362 369
88. R Sandyk H Fisher 1989 L-tryptophan supplementation in Parkinson's disease. Int J Neurosci 45 3-4 215 219
89. B Scatton F Javoy-Agid L Rouquier B Dubois Y Agid 1983 Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275 2 321 328
90. CJ Schmidt GM Fadayel CK Sullivan VL Taylor 1992 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223 1 65 74
91. JA Schmitt BL Jorissen S Sobczak MP van Boxtel E Hogervorst NE Deutz WJ Riedel 2000 Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol 14 1 21 29
92. AP Sempere J Duarte C Cabezas LE Claveria F Coria 1995 Aggravation of parkinsonian tremor by cisapride. Clin Neuropharmacol 18 1 76 78
93. S Sobczak A Honig NA Nicolson WJ Riedel 2002 Effects of acute tryptophan depletion on mood and cortisol release in first-degree relatives of type I and type II bipolar patients and healthy matched controls. Neuropsychopharmacology 27 5 834 842
94. H Tanaka K Kannari T Maeda M Tomiyama T Suda M Matsunaga 1999 Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10 3 631 634
95. U Ungerstedt 1968 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 1 107 110
96. MJ Van Kroonenburgh AFG Leentjens FRJ Verhey F Vreeling J Troost 2001 Imaging of 5-HT2a receptors in Parkinson's disease. J Nucl Med 42 Suppl 227
97. HM Van Praag S De Haan 1979 Central serotonin metabolism and frequency of depression. Psychiatry Res 1 219 224
98. R Volpi P Caffarra S Boni A Scaglioni L Malvezzi A Saginario P Chiodera V Coiro 1997 ACTH/cortisol involvement in the serotonergic disorder affecting the parkinsonian brain. Neuropsychobiology 35 2 73 78
99. R Volpi P Caffarra A Scaglioni S Boni A Saginario P Chiodera V Coiro 1997 Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology 35 2 79 83
100. FC Zhou S Bledsoe J Murphy 1991 Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556 1 108 116
101. J Zoldan G Friedberg M Livneh E Melamed 1995 Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45 7 1305 1308